RxDoctor Payments Data

Ashlie Losee, APRN

Psychiatric/Mental Health · Ammon, IDNPI 1760115505

Payments from drug & device makers

$761in general payments, 2019–2025

Across 34 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$185
  • Axsome Therapeutics, Inc.$158
  • Otsuka America Pharmaceutical, Inc.$142
  • Vanda Pharmaceuticals Inc.$70
  • AbbVie$67
  • Alkermes, Inc.$35
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$761100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$761 in reported general payments places this provider in the 50th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$12,256
Medicare patients
32
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate77$269,457
VraylarCariprazine Hcl13$17,683
Aripiprazole54$8,616
Lurasidone Hcl37$7,459
Clozapine99$5,562
Divalproex Sodium ErDivalproex Sodium46$5,332
Atomoxetine Hcl18$4,531
Duloxetine Hcl111$2,106
Ziprasidone Hcl27$1,971
Prazosin Hcl91$1,870
Olanzapine69$1,682
Risperidone93$1,504
Haloperidol Decanoate30$1,225
Hydroxyzine Hcl54$868
Quetiapine Fumarate58$802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$67$17,68313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Ammon

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →